← Back to Clinical Trials
Recruiting NCT05679739

NCT05679739 NEUROprotection Via optimizINg Cerebral Blood Flow afTer cArdiaC arresT (NEURO-INTACT) Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05679739
Status Recruiting
Phase
Sponsor National University Hospital, Singapore
Condition Out-Of-Hospital Cardiac Arrest (OHCA)
Study Type INTERVENTIONAL
Enrollment 49 participants
Start Date 2023-08-29
Primary Completion 2025-08

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 79 Years
Study Type INTERVENTIONAL
Interventions
Individualized blood pressure strategy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 49 participants in total. It began in 2023-08-29 with a primary completion date of 2025-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This single-center proof of concept study aims to assess the efficacy of a blood pressure strategy targeting person- and time-specific cerebral blood flow compared with standard-of-care using neuron-specific enolase as a quantitative biomarker of brain injury. Our central hypothesis is that an individualized blood pressure strategy targeting cerebral perfusion will reduce the extent of brain injury as indicated by changes in levels of neuron-specific enolase from baseline at 72 hours. To test this hypothesis, we will recruit 49 patients to an individualized blood pressure management strategy targeting cerebral blood flow, where optimal blood pressure will be serially calculated by the ICM+ brain monitoring software (Cambridge, UK) using inputs from transcranial Doppler ultrasound and near-infrared spectroscopy.

Eligibility Criteria

Inclusion Criteria: 1. At least 21 years of age 2. Comatose defined as not being able to obey verbal commands and no verbal response to pain after sustained ROSC. Exclusion Criteria: 1. ≥ 80 years old at time of enrolment 2. Pregnant patients 3. Limitations of care or life support therapy withdrawn within 24 hours of admission

Contact & Investigator

Central Contact

Shir Lynn Lim

✉ shir_lynn_lim@nuhs.edu.sg

📞 69082222

Principal Investigator

Shir Lynn Lim

PRINCIPAL INVESTIGATOR

National University Hospital, Singapore

Frequently Asked Questions

Who can join the NCT05679739 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 79 Years, studying Out-Of-Hospital Cardiac Arrest (OHCA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05679739 currently recruiting?

Yes, NCT05679739 is actively recruiting participants. Contact the research team at shir_lynn_lim@nuhs.edu.sg for enrollment information.

Where is the NCT05679739 trial being conducted?

This trial is being conducted at Singapore, Singapore.

Who is sponsoring the NCT05679739 clinical trial?

NCT05679739 is sponsored by National University Hospital, Singapore. The principal investigator is Shir Lynn Lim at National University Hospital, Singapore. The trial plans to enroll 49 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology